Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

Investing.com -- Shares of Genmab (NASDAQ:GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Emily Field from Barclays maintained a Buy rating on Genmab A/S (0MGB – Research Report), with a price target of ...

Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...

Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45th Annual TD Cowen ...

Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...